不同公司腹膜透析系统的技术存活差异
该研究纳入1995至2014年澳大利亚和新西兰所有开始腹膜透析的患者,按初始PD公司系统分组,比较技术失败与死亡的复合结局。与Baxter相比,Gambro和Fresenius系统的技术失败或死亡率显著升高,但患者生存无差异。
要点
- 不同公司PD系统的技术存活存在差异,Gambro和Fresenius系统风险高于Baxter。
- 患者生存率在三种PD系统间无显著差异。
- 结论需前瞻性随机对照试验证实。
核心结论
- 不同公司制造的PD系统可能与PD技术存活的重要差异相关。
- 需足够效力的前瞻性随机对照临床试验确认。
研究设计与样本
- 研究纳入1995至2014年澳大利亚和新西兰所有开始PD的患者。
- 按初始PD公司系统分组,主要结局为PD技术失败和死亡的复合终点。
主要发现
- 所有患者技术失败或死亡的中位时间为625天(IQR 318-1114):Baxter 629.5天(IQR 321-1121),Fresenius 620.5天(IQR 311-1069),Gambro 538天(IQR 272-1001)(P=0.023)。
- 与Baxter相比,Gambro系统技术失败或死亡率调整IRR为1.46(95%CI 1.33-1.62),Fresenius为1.10(95%CI 1.01-1.19)。
- 三种PD系统间患者生存无差异。
临床怎么用
- 选择PD系统时需考虑不同公司产品可能与技术存活差异相关。
- Gambro和Fresenius系统使用者的技术失败或死亡风险较高,应加强监测。
局限性
- 为观察性研究,不能排除混杂因素。
- 需前瞻性随机对照试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A number of peritoneal dialysis (PD) systems are available but there have been few studies comparing them. The aim of this study was to examine technique failure and patient survival between different PD company systems. METHODS: The study included all patients who commenced PD between 1995 and 2014 in Australia and New Zealand. Groups were compared according to the initial PD company system that they received. The primary outcome was a composite of PD technique failure and death. RESULTS: A total of 16 575 patients commenced PD using systems manufactured by Baxter [n = 13 438 (81%)], Fresenius Medical Care [n = 2848 (17%)] or Gambro [n = 289 (2%)]. Of these, 11 870 (72%) developed technique failure, including 5421 (33%) who died. The median time to technique failure or death for all patients was 625 [interquartile range (IQR) 318-1114] days: 629.5 (IQR 321-1121) days with Baxter, 620.5 (IQR 311-1069) days with Fresenius Medical Care and 538 (IQR 272-1001) days with Gambro systems (P = 0.023). There was a statistically significant increase in technique failure or mortality rates in patients on Gambro {adjusted incidence rate ratio [IRR] 1.46 [95% confidence interval (CI) 1.33-1.62]} and Fresenius [adjusted IRR 1.10 (95% CI 1.01-1.19)] systems compared with Baxter systems. No difference in patient survival was observed between the three PD systems. CONCLUSIONS: PD systems manufactured by different companies may be associated with important differences in PD technique survival. This needs to be confirmed with adequately powered, prospective randomized controlled clinical trials.
引用
- Boudville N, Ullah S, Clayton P, et al. Differences in peritoneal dialysis technique survival between patients treated with peritoneal dialysis systems from different companies. Nephrol Dial Transplant. 2019. PMID: 30561719. doi:10.1093/ndt/gfy340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。